Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- DSP Aims for Better Communications with Wholesalers, Regulators with Tokyo-Osaka Two Head Office System
August 8, 2013
- Top 4 Wholesalers Report Average Price Agreement Rate of 63.4% at End of June, Down 7.5 Points from 2 Years Prior
August 8, 2013
- Takeda to Merge Bio Development Center following Acquisition of Its Operations
August 7, 2013
- Eli Lilly Paid 16.3 Billion Yen in 2012 to Doctors, Medical Institutions
August 7, 2013
- Janssen, Mochida to Comarket Pain Treatment Tramcet Combination Tablets from October
August 6, 2013
- Toyama Chemical Starts Commercial Production at Newly-Established Plant for Injectables
August 6, 2013
- Eisai Sales Up 5.0%, Helped by Growth of New Products
August 5, 2013
- Sales of Eisai’s Obesity Treatment Belviq Exceeds US$10 Million Three Weeks after Launch
August 5, 2013
- Astellas’s First-Quarter Net Profit Down 27% Despite Increases in Sales; 5% Decline in Domestic Sales Due to Impact of Generics
August 5, 2013
- MTPC to Consolidate Domestic Manufacturing Plants, Transferring Ashikaga Plant to CMIC Holdings
August 5, 2013
- Apo Plus to Hire 1,000 Contract MRs by 2013-End
August 2, 2013
- Daiichi Sankyo to Cut 400 to 500 Workers in Europe
August 2, 2013
- Daiichi Sankyo Sales Up 4% in First Quarter, Profits Down due to Ranbaxy Business Slump
August 2, 2013
- Takeda April-June Sales Up 3%, but Operating Profit Logs Double-Digit Fall
August 2, 2013
- Sanofi Files NDA for Prostate Cancer Treatment Cabazitaxel in Japan
August 2, 2013
- Prospects for World’s 1st FD Treatment Remain Unclear; Success Will Depend on Raising Awareness, Role of Endoscopy
August 2, 2013
- Pfizer, Takeda Launch RA Treatment Xeljanz, Prepare for Promoting Proper Use of Drug
August 1, 2013
- Takeda Paid 40 billion Yen to Healthcare Professionals in FY2012
August 1, 2013
- 2 Beijing-Based Wholesalers Could Serve as Point of Contact for Japanese Drug Makers: Mr Yoda of Medipal Holdings
August 1, 2013
- PII Study of Renal Anemia Treatment Codeveloped by FibroGen Starts in Japan: Astellas
August 1, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…